Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial.

ABSTRACT:

Purpose

The aim of this study was to evaluate whether indomethacin eye drops and intravitreal ranibizumab (IVR) injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularization (CNV).

Participants and methods

This was a randomized, prospective pilot study of eyes with new-onset CNV. Fifty-eight patients were randomized 1:1 into a ranibizumab monotherapy (RM) group and a ranibizumab plus indomethacin (RI) group. All patients received monthly 0.5 mg IVR injections for 3 months, followed by monthly injections administered as needed. RI group patients also self-administered one drop of 0.5% indomethacin three times a day for 12 months. All patients were followed up for 12 months.

Results

At 12 months, both groups showed s

SUBMITTER: Russo A 

PROVIDER: S-EPMC5877501 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature